Table 1 Clinical characteristics of tuberculosis patients and matched controls from the same donor

Age, year, median (IQR)

42(35–48)

33(27–46]

0.042

Male, n (%)

25 (80.6)

21(67.7)

0.246

BMI, kg/m², median (IQR)

21.8(19.96–23.28)

21.2(19.40–24.10)

0.446

Hemodialysis, n (%)

25 (80.6)

23(74.2)

0.544

Peritoneal dialysis, n (%)

4 (12.9)

5(16.1)

0.718

Non-dialysis, n(%)

2 (6.5)

3(9.7)

0.641

Dialysis time, month, median (IQR)

12(7–24)

10(4–23)

0.799

Primary transplantation, n(%)

30 (96.8)

31(100)

0.313

Secondary transplantation, n (%)

1 (3.2)

0

0.313

Cause of ESRD

 Chronic glomerulonephritis, n(%)

22 (71.0)

25(80.6)

0.313

 Diabetic nephropathy, n(%)

5 (16.1)

3(9.7)

0.449

 Hypertensive nephropathy, n(%)

3 (9.7)

3(9.7)

1

 IgA nephropathy, n(%)

1 (3.2)

0

0.313

Immunosuppressive regimen

 Tacrolimus + mycophenolate + methylprednisolone, n(%)

25 (80.6)

30(96.8)

0.108

 Cyclosporine + mycophenolate + methylprednisolone, n(%)

6 (19.4)

1(3.2)

0.108

 Onset time post-transplant, month, median (IQR)

11(5–24)

Comorbidity and complication

 Hypertension., n(%)

30 (96.8)

29(93.5)

0.554

 Diabetes., n(%)

11(35.5)

2(6.5)

0.013

 Hepatitis B and C, n(%)

9 (29.0)

2(6.5)

0.046

 BK infection, n(%)

6 (19.4)

0

0.108

 CMV infection, n(%)

7 (22.6)

1(3.2)

0.058

Induction immunosuppression

 ATG, n(%)

18 (58.0)

17(54.9)

0.798

 Basiliximab, n(%)

7 (22.6)

9(29.0)

0.562

 No-induction, n(%)

6 (19.4)

5(16.1)

0.74